Companies › WestVac Biopharma
2 active drug programs in 8 registered trials: 5 Phase 2, 3 Phase 3; Infectious disease.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Delamanid Prodrug converted to reactive species that inhibits mycobacterial cell wall synthesis | – | Phase 2 | Tuberculosis; Tuberculosis, MDR; Pulmonary Tuberculosis; Drug-resistant Tuberculosis … | – |
| JDB0131 benzenesulfonate tablets Mycobacterium tuberculosis ATP synthase inhibitor | – | Phase 2 | Tuberculosis | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07170800 | JDB0131 benzenesulfonate tablets | Phase 2 | Tuberculosis | Infectious disease | Feb 2026 |
| NCT07170800 | Delamanid | Phase 2 | Tuberculosis | Infectious disease | Feb 2026 |
| NCT03568383 | Delamanid | Phase 3 | Tuberculosis, MDR | Infectious disease | Nov 2026 |
| NCT06081361 | Delamanid | Phase 3 | Pulmonary Tuberculosis | Infectious disease | Dec 2026 |
| NCT05766267 | Delamanid | Phase 2 | Tuberculosis, Pulmonary | Infectious disease | Dec 2026 |
| NCT05556746 | Delamanid | Phase 2 | Tuberculosis, Pulmonary | Infectious disease | Jan 2027 |
| NCT06649721 | Delamanid | Phase 3 | Drug-resistant Tuberculosis | Infectious disease | Feb 2027 |
| NCT03828201 | Delamanid | Phase 2 | Tuberculosis, Multidrug-Resistant | Infectious disease | May 2027 |
No annotated target.
–
Restorbio Vasomune Therapeutics Altesa Biosciences Eagle Pharmaceuticals Code Pharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.